[Comment] Safety and immunogenicity of a recombinant adenovirus vector-based Ebola vaccine

The 2013 –16 epidemic of Ebola virus disease in west Africa was a game changer—not only in terms of the location and dimension of the outbreak and with regards to many painful lessons learnt about the epidemiology, features, and management of the disease, but also in terms of furthering the development o f monoclonal antibody treatments1,2 and, most importantly, vaccines. Besides the replicative vector-based rVSV-ZEBOV vaccine,3,4 which has yielded high efficacy in an interim analysis of an open-label, cluster-randomised ring vaccination trial in Guinea,5 a range of other candidate vaccines have pro gressed into clinical development.
Source: LANCET - Category: Journals (General) Authors: Tags: Comment Source Type: research